Medline ® Abstract for Reference 16
of 'Molecularly targeted therapy for metastatic melanoma'
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma
Chapman PB, Hauschild A, Robert C, et AL
J Clin Oncol. 2012;30(15_suppl):8502.